埃萬妥單抗

埃萬妥單抗
埃萬妥單抗的抗MET英语hepatocyte growth factor receptor臂端(藍)與人的信号素結構域英语hepatocyte growth factor receptor紫褐色英语puce)結合的空間填充模型PDB 6wvz
单克隆抗体
种类完整抗体
目標表皮生长因子受体 (EGFR) 和上皮間質轉化英语Mesenchymal–epithelial transition (MET)
臨床資料
商品名英语Drug nomenclatureRybrevant
其他名稱JNJ-61186372, amivantamab-vmjw
AHFS/Drugs.comMonograph
MedlinePlusa621034
核准狀況
懷孕分級
给药途径靜脈注射
藥物類別化学疗法
ATC碼
法律規範狀態
法律規範
识别信息
CAS号2171511-58-1
DrugBank
UNII
KEGG
化学信息
化学式C6472H10014N1730O2023S46
摩尔质量145,902.15 g·mol−1

埃萬妥單抗INN:Amivantamab)用于治疗非小細胞肺癌英语Non-small-cell lung cancer[8] [9]。特別是針對表皮生长因子受体(EGFR)外显子20處插入突变,且其他治疗无效的晚期患者[8]。通过静脉注射给药[8]

常见副作用包括皮疹、输液反应指甲周围感染、肌肉和关节疼痛、呼吸短促、恶心、疲倦、肿胀、口腔溃疡、咳嗽和便秘[8]。其他副作用可能包括肺炎、眼部问题、低钾高血糖低钠和肝脏炎症[8]。孕期使用可能對婴儿有害[8]。它是一种雙特異性單株抗體英语Bispecific monoclonal antibody,可与表皮生长因子(EGF)受体和上皮間質轉化英语Mesenchymal–epithelial transition(MET)受体结合[8]

埃萬妥單抗于2021年在美国和欧洲取得医疗使用許可[8] [9]

参考文獻

  1. ^ 1.0 1.1 Rybrevant (Janssen-Cilag Pty Ltd). Therapeutic Goods Administration (TGA). 13 January 2023 [18 April 2023]. (原始内容存档于27 March 2023). 
  2. ^ Rybrevant Product information. Health Canada. 25 April 2012 [29 June 2022]. (原始内容存档于29 June 2022). 
  3. ^ Summary Basis of Decision - Rybrevant. Health Canada. 23 October 2014 [6 August 2022]. (原始内容存档于6 August 2022). 
  4. ^ Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. (原始内容存档于26 May 2021). 
  5. ^ FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer. U.S. Food and Drug Administration (FDA) (新闻稿). 21 May 2021 [21 May 2021]. (原始内容存档于21 May 2021).  公有领域 本文含有此來源中屬於公有领域的内容。
  6. ^ FDA grants accelerated approval to amivantamab-vmjw for mNSCLC. U.S. Food and Drug Administration (FDA). 21 May 2021 [21 May 2021]. (原始内容存档于22 May 2021).  公有领域 本文含有此來源中屬於公有领域的内容。
  7. ^ Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. (原始内容存档于23 April 2022).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. (原始内容存档于26 May 2021). 
  9. ^ 9.0 9.1 Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. (原始内容存档于23 April 2022).  Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

延伸閱讀

外部連結

  • Clinical trial number NCT02609776 for "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)" at ClinicalTrials.gov

 

Prefix: a b c d e f g h i j k l m n o p q r s t u v w x y z 0 1 2 3 4 5 6 7 8 9

Portal di Ensiklopedia Dunia